In a fresh report, released online today in Clinical Infectious Diseases, IDSA determined only seven new drugs in development for the treating infections caused by multidrug-resistant gram-negative bacilli (GNB) bacteria. GNB, which include the “problem bacterias” to that your Centers for Disease Control and Prevention (CDC) alerted the public in its March 2013 Vital Signs report, represent the most pressing medical need.
Henry Chambers, MD, chair of IDSA’s Antimicrobial Resistance Committee (ARC). Helen W. Boucher, MD, lead author of the policy paper and a member of IDSA’s Board of Directors and ARC. Ironically, at this urgent time of greatest need, the number of pharmaceutical companies buying antibiotic R&D has plummeted. New antibiotics are critically necessary to save the full lives of individuals such as Josh Nahum, a wholesome 27-year-old man who died from an overwhelming Enterobacter aerogenes infection as he was recovering in the hospital after a skydiving accident.
Although his doctors tried desperately to save lots of Josh, they ran out of antibiotics to treat this virulent bug. IDSA first warned of the looming antibiotic apocalypse with its 2004 record, “Bad Bugs, No Drugs.” 50 other medical societies and organizations Almost, including the American Medical Association, have endorsed the 10 x ’20 initiative up to now. IDSA President David A. Relman, MD.
- Product(s): Water; Flavored Beverages
- No much longer need monthly annuity payments
- Hedge Fund Auditors
- FSA – Fellow of the Society of Actuaries – honored by the Society of Actuaries
In August 2016, the FASB released AS 2016-15, … Read the rest


